TG Therapeutics (TG Therapeutics) Cyclically Adjusted PS Ratio : 66.52 (As of May. 14, 2024)

View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-05-14), TG Therapeutics's current share price is $17.96. TG Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.27. TG Therapeutics's Cyclically Adjusted PS Ratio for today is 66.52.

The historical rank and industry rank for TG Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

TGTX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 37.17 Med: 695.5 Max: 4896
Current: 63.4

During the past years, TG Therapeutics's highest Cyclically Adjusted PS Ratio was 4896.00. The lowest was 37.17. And the median was 695.50.

TGTX's Cyclically Adjusted PS Ratio is ranked worse than
93.76% of 513 companies
in the Biotechnology industry
Industry Median: 5.53 vs TGTX: 63.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TG Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.434. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.27 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation

TG Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for TG Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Cyclically Adjusted PS Ratio Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cyclically Adjusted PS Ratio

Get a 7-Day Free Trial

1,581.96

833.08

79.26

TG Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial															697.52	677.81	46.79	79.26	55.68

Competitive Comparison of TG Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, TG Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Cyclically Adjusted PS Ratio falls into.

TG Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

TG Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio	=	Share Price	/	Cyclically Adjusted Revenue per Share
	=	17.96	/	0.27
	=	66.52

TG Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, TG Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare	=	Revenue per Share	/	CPI of Mar. 2024 (Change)	*	Current CPI (Mar. 2024)
	=	0.434	/	129.4194	*	129.4194
	=	0.434

Current CPI (Mar. 2024) = 129.4194.

TG Therapeutics Quarterly Data

	Revenue per Share	CPI	Adj_RevenuePerShare
201406	0.001	100.560	0.001
201409	0.001	100.428	0.001
201412	0.001	99.070	0.001
201503	0.001	99.621	0.001
201506	0.001	100.684	0.001
201509	0.001	100.392	0.001
201512	0.001	99.792	0.001
201603	0.001	100.470	0.001
201606	0.001	101.688	0.001
201609	0.001	101.861	0.001
201612	0.001	101.863	0.001
201703	0.001	102.862	0.001
201706	0.001	103.349	0.001
201709	0.001	104.136	0.001
201712	0.001	104.011	0.001
201803	0.001	105.290	0.001
201806	0.001	106.317	0.001
201809	0.000	106.507	0.000
201812	0.000	105.998	0.000
201903	0.000	107.251	0.000
201906	0.000	108.070	0.000
201909	0.000	108.329	0.000
201912	0.000	108.420	0.000
202003	0.000	108.902	0.000
202006	0.000	108.767	0.000
202009	0.000	109.815	0.000
202012	0.000	109.897	0.000
202103	0.006	111.754	0.007
202106	0.012	114.631	0.014
202109	0.015	115.734	0.017
202112	0.018	117.630	0.020
202203	0.015	121.301	0.016
202206	0.004	125.017	0.004
202209	0.001	125.227	0.001
202212	0.001	125.222	0.001
202303	0.056	127.348	0.057
202306	0.114	128.729	0.115
202309	1.064	129.860	1.060
202312	0.282	129.419	0.282
202403	0.434	129.419	0.434

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

TG Therapeutics (NAS:TGTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

TG Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (TG Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Cyclically Adjusted PS Ratio

Comparable Companies

Traded in Other Exchanges

NKB2:Germany NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Executives

Laurence N Charney	director	MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power	officer: CFO, Secretary and Treasurer	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss	director, officer: CEO and President	750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial	director	C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard	director	C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume	director	3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy	director	C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u.	10 percent owner	3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum	director	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc	10 percent owner	787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019